The recognition included breast cancer cell lines normally resistant to NK recognition due to a lack of transmembrane ligands for NK cells or cells resistant to trastuzumab, HER-2-directed antibody, for instance, MCF-7 and MDA MB 453 that express low levels of HER-2. This evidence concerns the gene ERBB2 and breast cancer.